Epoetin to improve outcomes in severe trauma ICU patients
Part of Brain & nervous system, Injuries & trauma clinical trials.
This trial tests epoetin alfa (a blood-building medicine) to help reduce death and severe disability in critically ill trauma patients in the ICU. You may be considered if your ICU team expects a longer stay and the timing after injury is early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You were admitted to the ICU from a traumatic injury within 24 hours
- You are on a breathing machine through a tube (invasive mechanical ventilation)
- The ICU team expects you to stay in the ICU for at least 48 hours
- Your hemoglobin level is not above the usual “normal” range used at your hospital
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares giving whole blood versus standard care in adults with severe trauma and dangerous blood loss (hemorrhagic shock). The goal is to see if whole blood helps stabilize patients faster and improves outcomes after major bleeding.
This trial tests whether a combination of epoetin alfa (a medicine that boosts red blood cell production) and iron derisomaltose (an iron supplement) can safely treat anemia in people with sepsis or septic shock. It may help improve your energy and recovery.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This Phase 3 trial studies whether erythropoietin (a medicine related to red-blood-cell growth) can improve outcomes for newborns with moderate to severe brain injury after birth. The study focuses on babies born in low- and middle-income countries and aims to reduce harm from this early brain condition.
This study tests two medicines, luspatercept and epoetin, to see which one helps the body make more red blood cells after a stem cell transplant. If you have low red blood cell counts after your transplant, this trial may help improve your energy and reduce the need for transfusions.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Hear when a new Trauma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.